Fulcrum Therapeutics
- Revenue$8.8 MFY, 2020
- Market Capitalization$207.2 M2022-06-23
OverviewSuggest Edit
The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation.
The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
| Type | Public | |
| Founded | 2016 | |
| HQ | Cambridge, MA, US | Map |
| Website | fulcrumtx.com |
Recent NewsAll News
- Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
- Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
- Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
- Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Key People/Management at Fulcrum Therapeutics
Bryan Stuart
President, Chief Executive Officer, Board Member
Judith Dunn
President, Research & Development
Nicole T. Gallagher
Director, Administration
Kim Hazen
Senior Vice President, Human Resources
Curtis Oltmans
General Counsel
Peter Thomson
Vice President, Finance and Accounting
Fulcrum Therapeutics Office Locations
Fulcrum Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
26 Landsdowne St
Fulcrum Therapeutics Financials and Metrics
Fulcrum Therapeutics Revenue
Fulcrum Therapeutics's revenue was reported to be $8.82 m in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 8.8m |
Net income (FY, 2020) | (70.8m) |
EBIT (FY, 2020) | (71.6m) |
Market capitalization (23-Jun-2022) | 207.2m |
Closing stock price (23-Jun-2022) | 5.1 |
Cash (31-Dec-2020) | 57.1m |
Fulcrum Therapeutics's current market capitalization is $207.2 m.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | 3.3 x |
Fulcrum Therapeutics Cybersecurity Score
Fulcrum Therapeutics Environment, Social & Governance (ESG) Ratings
Fulcrum Therapeutics Online and Social Media Presence
679 Twitter followers
Fulcrum Therapeutics has 679 Twitter Followers. The number of followers has increased 3.5% month over month and increased 8.5% quarter over quarter
Fulcrum Therapeutics's Trends
Twitter Engagement Stats for @FulcrumTx
1k
Tweets
155
Following
679
Followers
19
Tweets last 30 days
2.8
Avg. likes per Tweet
73.7%
Tweets with engagement
Fulcrum Therapeutics News and Updates
June 10, 2022
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint
May 12, 2022
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development
May 05, 2022
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Bo…
August 16, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offer…
August 12, 2021
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,0…
August 11, 2021
Thinking about buying stock in Newtek Business Services, Fulcrum Therapeutics, Gamida Cell, PubMatic, or Falcon Capital Acquisition?
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEWT, FULC, GMDA, PUBM, and SHCR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Fulcrum Therapeutics Blogs
May 09, 2022
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
– In itial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress – – Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022 – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) --
May 02, 2022
Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 financial results will be
February 10, 2022
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the
January 06, 2022
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
Content Import
Thu, 01/06/2022 - 08:02
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 6, 2022 at 8:02 AM EST
This release is a …
November 03, 2021
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
Content Import
Wed, 11/03/2021 - 07:00
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
November 3, 2021 at 7:00 AM EDT
This release is a backfill from…
September 02, 2021
Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following
Fulcrum Therapeutics Frequently Asked Questions
When was Fulcrum Therapeutics founded?
Fulcrum Therapeutics was founded in 2016.
Who are Fulcrum Therapeutics key executives?
Fulcrum Therapeutics's key executives are Bryan Stuart, Judith Dunn and Nicole T. Gallagher.
How many employees does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 432 employees.
What is Fulcrum Therapeutics revenue?
Latest Fulcrum Therapeutics annual revenue is $8.8 m.
What is Fulcrum Therapeutics revenue per employee?
Latest Fulcrum Therapeutics revenue per employee is $20.4 k.
Who are Fulcrum Therapeutics competitors?
Competitors of Fulcrum Therapeutics include Xenotherapeutics Inc, CytoTools and PamBio.
Where is Fulcrum Therapeutics headquarters?
Fulcrum Therapeutics headquarters is located at 26 Landsdowne St, Cambridge.
Where are Fulcrum Therapeutics offices?
Fulcrum Therapeutics has an office in Cambridge.
How many offices does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies